The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).
 
Daniel Sentana Lledo
No Relationships to Disclose
 
Xiangying Chu
No Relationships to Disclose
 
David Frazier Jarrard
No Relationships to Disclose
 
Michael Anthony Carducci
Consulting or Advisory Role - Acrivon Therapeutics; AstraZeneca; Pfizer; Sanofi
Speakers' Bureau - Remedica
Research Funding - Arcus Biosciences (Inst); Celgene/Bristol-Myers Squibb (Inst); Merck (Inst); pfizer (Inst)
 
Robert S. DiPaola
No Relationships to Disclose
 
Lynne I. Wagner
Consulting or Advisory Role - Athenex; Celgene
Travel, Accommodations, Expenses - Celgene
 
David Cella
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Celcuity; Fulcrum Therapeutics; GlaxoSmithKline; Immunogen; Ipsen; Novartis; Pfizer
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); PledPharma (Inst); Regeneron (Inst)
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Alicia K. Morgans
Honoraria - Advanced Accelerator Applications; Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Exelixis; Genentech; Janssen; Janssen; Janssen Oncology; Merck; Myovant Sciences; Pfizer; Sanofi; Telix Pharmaceuticals
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Exelixis; Janssen; Lantheus Medical Imaging; Merck; Myovant Sciences; Myovant Sciences; Myriad Genetics; Novartis; Sanofi
Research Funding - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Dendreon; Genentech; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Sanofi; Telix Pharmaceuticals